Clinical Trials

  • Principal Investigator:

    Nobuko Hijiya, MD
    The purpose of this study is to learn more about the treatment of children and teenagers whose leukemia has come back (has relapsed) or has not gone away after other treatments (is refractory). Participants will receive the study drug, called carfilzomib in combination with standard chemotherapy, that are dexamethasone, daunorubicin, vincristine and PEG-asparaginase. The study consist of 3 periods: screening, treatment and end of study period. Participants with stable disease or better response at the end of the Induction Cycle will be offered an optional cycle of Consolidation chemotherapy.
  • Principal Investigator:

    Luca Szalontay, MD
    The purpose of this study is to determine if a study drug called pembrolizumab is safe and effective in the treatment of children and adolescents who have advanced melanoma, or advanced, relapsed, or refractory PD-L1 positive malignant solid tumor or other lymphoma, relapsed or refractory classical Hodgkin lymphoma (rrcHL), advanced, relapsed or refractory microsatellite-instability-high (MSI-H) solid tumor. Participants might be at least 6 months ( 3 years rrcHL) to less than 18 years old and able to provide the sample for testing the PD-L1 (programmed cell death ligand 1) purpose from an...
  • Principal Investigator:

    Meyer Kattan, MD
    We are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to asthma symptoms, and more! If you live in the city or surrounding counties and have an interest in participating in research studies, you may be eligible to join a registry of participants. Our research focuses on children, but all ages are eligible to join. Contribute to...
  • Principal Investigator:

    Meyer Kattan, MD
    We are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to asthma symptoms, and more! If you live in the city or surrounding counties and have an interest in participating in research studies, you may be eligible to join a registry of participants. Our research focuses on children, but all ages are eligible to join. Contribute to...
  • Principal Investigator:

    Ilene Fennoy, MD
    We know that puberty is a major time of change! Adolescents develop new decision-making skills and independence. It is possible that some of these changes are due to the hormonal changes during puberty. One of the ways we treat transgender and gender non-conforming teens is to suppress or "block" puberty. We know that this is a safe thing to do for teens because we use it in people who start puberty too early (precocious puberty) and in people who are born very small in order to prolong their growth potential. We are doing this study to continue to understand the impact of this therapy on...
  • Principal Investigator:

    Wendy Kay Chung, MD
    Study examining the genetic causes of birth defects.
  • Principal Investigator:

    Dani Dumitriu, MD, PhD
    The goal of this study is to address differences in health outcomes of newborns born to COVID-positive versus case-matched COVID negative mothers, as well as mothers who gave birth immediately prior to the pandemic arriving in NYC (February 2020) through review of charts and surveys with mothers. Additionally, the study will distribute a survey to physicians and other healthcare workers involved in newborn care to ask them about their clinical practices during the pandemic.
  • Principal Investigator:

    Dani Dumitriu, MD, PhD
    The goal of this study is to address differences in health outcomes of newborns born to COVID-positive versus case-matched COVID negative mothers, as well as mothers who gave birth immediately prior to the pandemic arriving in NYC (February 2020) through review of charts and surveys with mothers. Additionally, the study will distribute a survey to physicians and other healthcare workers involved in newborn care to ask them about their clinical practices during the pandemic.
  • Principal Investigator:

    Wendy Kay Chung, MD
    Each year more than 1,000 babies in the United States are born with a Congenital Diaphragmatic Hernia (CDH). For the majority of these babies, the cause of the CDH is unknown. DHREAMS (Diaphragmatic Hernia Research & Exploration; Advancing Molecular Science) study was created to improve the understanding of the molecular genetic basis of CDH. This National Institute of Health (NIH)-funded research team is composed of healthcare providers and researchers across the country, coordinated at Columbia University Medical Center. Multiple medical centers are enrolling individuals and families...
  • Principal Investigator:

    Wendy Kay Chung, MD
    Researchers at Columbia University Irving Medical Center are asking for your help. We are recruiting people 3-75 years of age. We are looking at how a report that contains information about genetic risk for some health conditions may help you and your care providers make decisions about your health. You may be eligible if you receive care at Columbia University Irving Medical Center. The study asks for a blood or saliva sample for DNA. Surveys can be completed online or over the phone. You will be compensated for participating in the study. To participate: https://redcap.vanderbilt.edu/...

Pages